Table of Contents
Publication date: March 2018Source: Advances in Chronic Kidney Disease, Volume 25, Issue 2Author(s): (Source: Advances in Chronic Kidney Disease)
Source: Advances in Chronic Kidney Disease - July 10, 2018 Category: Urology & Nephrology Source Type: research
Diabetes and the Kidney: Sweet Dreams
Publication date: March 2018Source: Advances in Chronic Kidney Disease, Volume 25, Issue 2Author(s): James E. Novak, Jerry Yee (Source: Advances in Chronic Kidney Disease)
Source: Advances in Chronic Kidney Disease - July 10, 2018 Category: Urology & Nephrology Source Type: research
Diabetic Kidney Disease (c. 2018)
Publication date: March 2018Source: Advances in Chronic Kidney Disease, Volume 25, Issue 2Author(s): Katherine R. Tuttle (Source: Advances in Chronic Kidney Disease)
Source: Advances in Chronic Kidney Disease - July 10, 2018 Category: Urology & Nephrology Source Type: research
The Global Epidemiology of Diabetes and Kidney Disease
Publication date: March 2018Source: Advances in Chronic Kidney Disease, Volume 25, Issue 2Author(s): Digsu N. Koye, Dianna J. Magliano, Robert G. Nelson, Meda E. PavkovThe prevalence of diabetes is increasing worldwide, with the greatest increases occurring in low- and middle-income countries. In most developed countries, type 2 diabetes is presently the leading cause of end-stage renal disease and also contributes substantially to cardiovascular disease. In countries with weaker economies type 2 diabetes is rapidly replacing communicable diseases as a leading cause of kidney disease and is increasingly competing for scarc...
Source: Advances in Chronic Kidney Disease - July 10, 2018 Category: Urology & Nephrology Source Type: research
Competing Risk of Death With End-Stage Renal Disease in Diabetic Kidney Disease
We present an example taken from the Action to Control Cardiovascular Risk in Diabetes, a randomized trial of people with type 2 diabetes at high risk for cardiovascular disease. Participants were stratified according to baseline markers of kidney disease: (1) no kidney disease; (2) low estimated glomerular filtration rate; (3) microalbuminuria alone; and (4) macroalbuminuria. The macroalbuminuria group had the highest risk for ESRD and demonstrated the most marked difference between the Kaplan-Meier and cumulative incidence estimator. Cox and Fine-Gray regression models yielded similar risk estimates for baseline characte...
Source: Advances in Chronic Kidney Disease - July 10, 2018 Category: Urology & Nephrology Source Type: research
Glycemic Control as Primary Prevention for Diabetic Kidney Disease
Publication date: March 2018Source: Advances in Chronic Kidney Disease, Volume 25, Issue 2Author(s): Richard J. MacIsaac, George Jerums, Elif I. EkinciImproving strategies to prevent the development and progression of CKD is a highly desirable outcome for all involved in the care of patients with diabetes. This is because CKD is a major factor contributing to morbidly and mortality in patients with diabetes. Furthermore, diabetes is the leading cause of ESRD in most developed countries. Although tight glucose control is now an established modality for preventing the development and progression of albuminuria, evidence is n...
Source: Advances in Chronic Kidney Disease - July 10, 2018 Category: Urology & Nephrology Source Type: research
New Glucose-Lowering Agents for Diabetic Kidney Disease
In conclusion, currently available trials have demonstrated renoprotective effects for certain glucagon-like peptide-1 receptor agonists, liraglutide and semaglutide, and the sodium-glucose cotransporter 2 inhibitors, empagliflozin and canagliflozin. Dipeptidyl peptidase-4 inhibitors did not show a significant renoprotective effect. Nevertheless, larger studies with respect to renoprotective effects of these 3 drug classes are currently being performed, and thus, no conclusions for all of these agents can yet be made. (Source: Advances in Chronic Kidney Disease)
Source: Advances in Chronic Kidney Disease - July 10, 2018 Category: Urology & Nephrology Source Type: research
Treatment of Diabetic Kidney Disease With Hypertension Control and Renin Angiotensin System Inhibition
Publication date: March 2018Source: Advances in Chronic Kidney Disease, Volume 25, Issue 2Author(s): Vikram Patney, Kunal Chaudhary, Adam Whaley-ConnellThe global incidence and prevalence of diabetes continues to expand due primarily to the influences of obesity and the contribution of obesity to the progression of type 2 diabetes mellitus. The rising prevalence of type 2 diabetes has driven an increase in rates of CKD in the past 3 decades in the United States. In turn, so have the rates for complications related to type 2 diabetes including CKD, eg, diabetic kidney disease (DKD). Although incident rates for DKD have stab...
Source: Advances in Chronic Kidney Disease - July 10, 2018 Category: Urology & Nephrology Source Type: research
Acute Kidney Injury and Progression of Diabetic Kidney Disease
Publication date: March 2018Source: Advances in Chronic Kidney Disease, Volume 25, Issue 2Author(s): Samuel Mon-Wei Yu, Joseph V. BonventreDiabetic kidney disease, commonly termed diabetic nephropathy (DN), is the most common cause of end-stage kidney disease (ESKD) worldwide. The characteristic histopathology of DN includes glomerular basement membrane thickening, mesangial expansion, nodular glomerular sclerosis, and tubulointerstitial fibrosis. Diabetes is associated with a number of metabolic derangements, such as reactive oxygen species overproduction, hypoxic state, mitochondrial dysfunction, and inflammation. In the...
Source: Advances in Chronic Kidney Disease - July 10, 2018 Category: Urology & Nephrology Source Type: research
Inflammatory Mechanisms as New Biomarkers and Therapeutic Targets for Diabetic Kidney Disease
Publication date: March 2018Source: Advances in Chronic Kidney Disease, Volume 25, Issue 2Author(s): Radica Z. Alicic, Emily J. Johnson, Katherine R. TuttleDiabetic kidney disease (DKD) is the leading cause of CKD and end-stage kidney disease (ESKD) worldwide. Approximately 30-40% of people with diabetes develop this microvascular complication, placing them at high risk of losing kidney function as well as of cardiovascular events, infections, and death. Current therapies are ineffective for arresting kidney disease progression and mitigating risks of comorbidities and death among patients with DKD. As the global count of ...
Source: Advances in Chronic Kidney Disease - July 10, 2018 Category: Urology & Nephrology Source Type: research
Role of Kidney Biopsies for Biomarker Discovery in Diabetic Kidney Disease
Publication date: March 2018Source: Advances in Chronic Kidney Disease, Volume 25, Issue 2Author(s): Helen C. Looker, Michael Mauer, Robert G. NelsonAlthough estimated glomerular filtration rate and albuminuria are well-established biomarkers of diabetic kidney disease (DKD), additional biomarkers are needed, especially for the early stages of the disease when both albuminuria and estimated glomerular filtration rate may still be in the normal range and are less helpful for identifying those at risk of progression. Traditional biomarker studies for early DKD are challenging because of a lack of good early clinical end poin...
Source: Advances in Chronic Kidney Disease - July 10, 2018 Category: Urology & Nephrology Source Type: research
The Promise of Systems Biology for Diabetic Kidney Disease
Publication date: March 2018Source: Advances in Chronic Kidney Disease, Volume 25, Issue 2Author(s): Frank C. Brosius, Wenjun JuDiabetic kidney disease (DKD) has a complex and prolonged pathogenesis involving many cell types in the kidney as well as extrarenal factors. It is clinically silent for many years after the onset of diabetes and usually progresses over decades. Given this complexity, a comprehensive and unbiased molecular approach is best suited to help identify the most critical mechanisms responsible for progression of DKD and those most suited for targeted intervention. Systems biological investigations provid...
Source: Advances in Chronic Kidney Disease - July 10, 2018 Category: Urology & Nephrology Source Type: research
Table of Contents for National Kidney Foundation 2018 Spring Clinical Meeting Abstracts April 10-14, 2018
Publication date: March 2018Source: Advances in Chronic Kidney Disease, Volume 25, Issue 2Author(s): (Source: Advances in Chronic Kidney Disease)
Source: Advances in Chronic Kidney Disease - July 10, 2018 Category: Urology & Nephrology Source Type: research
Implementation of a Program to Manage Transition of Care for End-Stage Renal Disease (ESRD) Patients Discharged from the Hospital
Publication date: March 2018Source: Advances in Chronic Kidney Disease, Volume 25, Issue 2Author(s): (Source: Advances in Chronic Kidney Disease)
Source: Advances in Chronic Kidney Disease - July 10, 2018 Category: Urology & Nephrology Source Type: research
Cardiovascular Risk Stratification Tool Evaluation in Renal Transplant Recipients
Publication date: March 2018Source: Advances in Chronic Kidney Disease, Volume 25, Issue 2Author(s): (Source: Advances in Chronic Kidney Disease)
Source: Advances in Chronic Kidney Disease - July 10, 2018 Category: Urology & Nephrology Source Type: research
